retatrutide type 2 diabetes phase 2 results 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished 🚨Breaking: Retatrutide's first Phase 3

Mol Cell2010 Oct 22;40(2):310-22

The recommendations, published in the medical journal JAMA, emphasize that these medications alone are not a solution to treating the global obesity epidemic

For delivered products, laboratory testing disclosed alarming concerns: Inconsistent Dosages: Some vials contained up to 39% more active ingredient than labeled, raising overdose risks

This change, effective as of February 21, 2025, impacts compounding pharmacies that had been producing off-brand versions during the shortage

It's also a reasonable choice if you prefer the feel of working with a dedicated medical practice rather than a large consumer health platform

If this is the case, she adds that its extremely important to be in contact with the patients therapist and/or psychiatrist